Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

British Journal of Cancer

Volumn 106, Issue 7, 2012, Pages 1268-1273

  Mochizuki, I ^a   Takiuchi, H ^b   Ikejiri, K ^c   Nakamoto, Y ^d   Kinugasa, Y ^e   Takagane, A ^f   Endo, T ^g   Shinozaki, H ^h   Takii, Y ⁱ   Takahashi, Y ^j   Mochizuki, H ^k   Kotake, K ^l   Kameoka, S ^m   Takahashi, K ⁿ   Watanabe, T ^o   Watanabe, M ^p   Boku, N ^q   Tomita, N ^r   Matsubara, Y ^s   Sugihara, K ^t  

^a Iwate Prefectural Central Hospital   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f HAKODATE GORYOUKAKU HOSPITAL   (Japan)

^g JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^h Imperial Foundation Saiseikai Utsunomiya Hospital   (Japan)

ⁱ NIIGATA CANCER CENTER HOSPITAL   (Japan)

^j OGAKI MUNICIPAL HOSPITAL   (Japan)

^k NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^l TOCHIGI CANCER CENTER   (Japan)

^m TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁿ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^o TEIKYO UNIVERSITY   (Japan)

^p KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r HYOGO COLLEGE OF MEDICINE   (Japan)

^s Translational Research Informatics Center   (Japan)

^t TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

adjuvant chemotherapy; colon cancer; phase III; S 1; UFT

Indexed keywords

FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UFT;

ADULT; AGED; ANEMIA; ANOREXIA; APLASTIC ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; COLON ADENOCARCINOMA; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; EPIPHORA; FATIGUE; FEMALE; HUMAN; HYPERPIGMENTATION; KERATITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN EXFOLIATION; STOMATITIS; TASTE AVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; OXONIC ACID; TEGAFUR; URACIL;

EID: 84862786909     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.86     Document Type: Article

References (17)

1. André T, Boni C, Mounedgi-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med 350: 2343-2351 (Pubitemid 38702845)
2. Cancer statistics in Japan 2010 (2010) Available at: http://www.fpcr.or. jp/publication/statistics.html
3. Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, Saito K, Zergebel C, Rosen LS (2011) Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102(2): 478-483
4. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28(2): 264-271
5. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzén F, Twelves C (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26(2): 2118-2123
6. Hassan A, Hurwitz JJ, Burkes RL (1998) Epiphora in patients receiving systemic 5-fluorouracil therapy. Can J Ophthalmol 33(1): 14-19 (Pubitemid 28166075)
7. Japanese Society for Cancer of the Colon and Rectum (2010) JSCCR Guidelines 2010 for the Treatment of Colorectal Cancer, (ed) pp 24-25. Kanehara & Co., Ltd: Tokyo
8. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K, Hase K, Oya M, Maeda K, Hirai T, Kameyama M, Shirouzu K, Muto T (2007) Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 141(1): 67-75 (Pubitemid 44918081)
9. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N (2007) Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 25(4): 424-430 (Pubitemid 350002991)
10. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A (2010) Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5): v70-v77
11. Lembersky BC, Wieand HS, Petrelli NJ, O0Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24(13): 2059-2064 (Pubitemid 46622115)
12. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Colon Cancer Version 2 (2011) Available at: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
13. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83(2): 141-145 (Pubitemid 30411708)
14. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18): 1810-1820 (Pubitemid 350044801)
15. Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O'Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22(17): 3466-3474 (Pubitemid 41103652)
16. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5): 548-557 (Pubitemid 26276346)
17. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Eng J Med 352: 2696-2704 (Pubitemid 41007824)